April 14, 2025 8:08am

Short term value continuation, enabling for near-term gain with an extended waiting for long-term share pricing

News: Verve Therapeutics (VERV +$0.69 aftermarket) the FDA has granted Fast Track designation for VERVE-102 for the treatment of patient groups with hyperlipidemia and high lifetime cardiovascular risk to reduce low-density lipoprotein cholesterol (LDL-C). VERVE-102 (a single-course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces disease-driving LDL-C) is currently being tested in the P1b Heart-2 clinical trial is evaluating the safety and tolerability in adult patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD) who require additional lowering of LDL-C.

Pre-open Indications: 1 Sell inti Strength, 1 Negative and 5 Positive Indications

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Friday’s night’s … RegMed Investors (RMi) Closing Bell: back on the green … https://www.regmedinvestors.com/articles/13877

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN), The chokehold got tighter cutting-off any capacity to lift multiple going concern at-risk marker … https://www.regmedinvestors.com/articles/13812

 

Monday: The pre-open Dow futures are UP +0.70% or (+290  points), the S&P futures UP +1.16% or (+62,75 points) and the Nasdaq futures are UP +1.24% or (+267.50 points)

  • Stock futures rose Monday, 4/14
  • European stock markets were broadly higher,
  • Asia-Pacific markets climbed Monday

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Friday: The Dow closed UP +619.05 points or +1.56%, the S&P closed UP +95.31 points or +1.81% while the Nasdaq close UP +337.14 points or +2.06%

Economic Data Docket: None – 2 Fed president speeches 

 

Q2- April – 6 negative and 3 positive closes

  • Q1/25 – March, 10 positive and 11 negative closes
  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the …  econs, it is still a mix of ups, downs and just uncertainty

Although … trending tickers … MY thoughts

Sell into Strength Indications:

Beam Therapeutics (BEAM) closed up +$0.84 to $15.47 after Thursday’s -$1.74 after Wednesday’s +$1.83, Tuesday’s -$0.76 after Monday’s +$0.13 with a positive +$0.09 or +0.58% aftermarket

  • <Jan. 2 price = $24.70, Feb. 3 price = $25.59, and March 3 = $25.10, April 1 = $16.48>
  • Simply Wall Street, “Given the large stake in the stock by institutions, Beam Therapeutics' stock price might be vulnerable to their trading decisions. A total of 7 investors have a majority stake in the company with 51% ownership. This set of investors may especially be concerned about the current loss, which adds to a one-year loss of 46% for shareholders.” Falters too much!

Negative Indications:

Mesoblast (MESO) closed down -$0.26 with a negative -$0.05 or -1.97% pre-market

  • <Jan. 2 price = $20.61, Feb. 3 price = $20.06, and March 3 = $15.41, April 1 = $11.90>
  • Its allogeneic cellular products derived from these platforms are manufactured from U.S. donors in the U.S. and designated as U.S. origin products. I don’t like financial reporting, should conform MORE to U.S. SEC standards

Positive Indication:

Alnylam Pharmaceuticals (ALNY) closed up +$11.49 to $232.77 after Thursday’s -$16.99, Wednesday’s +$18.95, Tuesday’s -$8.63 and last Monday’s -$2.79 with a positive +$1.00 or +0.42% pre-market.

  • <Jan. 2 price = $232.62, Feb. 3 price = $274.55, and March 3 = 243.53, April 1 = $255.76>

AxoGen (AXGN) closed up +$0.09 to $15.89 with a positive +$0.08 or +0.50% pre-market

  • <Jan. 2 price = $16.40, Feb. 3 price = $17.92, and March 3 = $19.29, April 1 = $17.81>
  • Have always liked, undervalued; I also think an M&A target

CRISPR Therapeutics (CRSP) closed up +$5.04 to $39.10 with a positive +$0.68 or +1.73% pre-market

  • <Jan. 2 price = $41.43, Feb. 3 price = $40.00, and March 3 = $41.29, April 1 = $33.14>
  • CRSP is dealing with a notable headwind. Administering therapies of this kind takes time; the biotech has yet to generate much revenue from it. However, CRISPR Therapeutics' Casgevy, which treats a pair of blood-related disorders, has little competition. Negative = management changes.

Lenz Therapeutics (LENZ) closed up +$1.72 to $20.26 after Thursday’s -$1.88, Wednesday’s +$2.10, Tuesday’s -$1.18 and Monday’s -$1.68 with a positive +$0.89 or -$4.39% pre-market

  • <Jan. 2 price = $28.29, Feb. 3 price = $25.37, and March 3 = 21.54, April 1 =$26.01>

 

The BOTTOM LINE:  Differential - Varying according to circumstances or relevant factors.

From Wall Street Journal (4/11/25) The U.S. biotech sector had already been through a brutal few years before the latest market crash. Robert F. Kennedy Jr.’s shake-up of the nation’s health agencies and persistently high interest rates are prompting it to sink even faster than the broader market, despite so far avoiding the worst of the tariff fallout.

  • More investors are even wondering if the whole model—risky science, costly funding, political uncertainty and long waits for payoffs—is simply broken.
  • For many of the nearly 200 companies trading below their cash value, it probably is. That illustrates the pitfalls of passively investing in an index for this sector.
  • Despite that bleak backdrop, there are still some opportunities for patient investors. After all, the U.S. is still the top spender on drugs by far. And that isn’t something RFK Jr. or President Trump is likely to change.
  • That isn’t to play down the overall risk. Even before RFK Jr.’s appointment, biotech was already reeling. Wave after wave of bankruptcies, shelved drug programs and layoffs had hollowed out the sector.
  • Dozens of companies that went public during the pandemic-era boom have been locked out of capital markets.
  • Over the past 5 years, the SPDR S&P Biotech ETF (XBI), which tracks small- and midcap biotech stocks, has lost 14%, while the S&P 500 has gained 89%.

 I am STILL in a RISK-ON mood! There is still a fog of uncertainty.

Volatility offered a minimal sign of sector equities recovery; market “cards” are “cold” after being whipsawed — and pressured — by relentless tariff headlines.

 

April ‘25: understand the “flow” of bad market and economic karma…

  • 4/11 - Friday closed positive with 28 positive, 5 negative and 2 flats
  • 4/10 - Thursday closed negative with 4 positive, 30 negative and 1 flat
  • 4/9 – Wednesday closed positive with 33 positive, 1 negative and 1 flat
  • 4/8 - Tuesday closed negative with 4 positive, 30 negative and 1 flat
  • 4/7 - Monday closed negative with 13 positive, 20 negative and 2 flats
  • 4/4 – Friday closed negative with 3 positive, 30 negative and 2 flats
  • 4/3 – Thursday closed negative with 2 positive, 32 negative and 1 flat
  • 4/2 - Wednesday closed positive with 9 positive, 25 negative and 1 flat
  • 4/1 - Tuesday closed negative with 5 positive, 28 negative and 2 flats

 

Brace ourself for more economics and tariff down trending affect?

 

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.